PR Newswire
TEL AVIV, Israel, May 30, 2017
TEL AVIV, Israel, May 30, 2017 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX),
a specialty clinical stage pharmaceutical Company specializing in the development of cannabinoid-based drugs, today announced
that the Company's management will present a company overview at three upcoming scientific and investor conferences in June:
The 7th Annual LD Micro Invitational:
|
Date:
|
Wednesday, June 7th, 2017
|
|
Time:
|
2:30 PM PST
|
|
Location:
|
Luxe Sunset Boulevard Hotel, Los Angeles, California
|
|
Presenter:
|
Josh Blacher, Chief Financial Officer
|
The 2017 Marcum MicroCap Conference:
|
Date:
|
Thursday, June 15th, 2017
|
|
Time:
|
10:30 AM EST
|
|
Location:
|
Grand Hyatt New York
|
|
Presenter:
|
Josh Blacher, Chief Financial Officer
|
The 27th Annual ICRS Symposium on the Cannabinoids:
|
Date:
|
June 22nd – 27th, 2017
|
|
Venue:
|
Poster Presentation
|
|
Location:
|
Le Centre Sheraton, Montréal, Canada
|
|
Presenter:
|
Dr. Elran Haber, Chief Executive Officer and Dr. Adi Zuloff-Shani, Chief
Technology Officer
|
About Therapix Biosciences:
Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives
and scientists, focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals.
With this focus, the company is currently engaged in two internal drug development programs based on repurposing an FDA approved
synthetic cannabinoid (dronabinol): THX-TS01 targets to the treatment of Tourette's syndrome; and THX-ULD01 targets the
high-value and under-served market of mild cognitive impairments. Please visit our website for more information at www.therapixbio.com.
For further information: Investor Contact: Josh Blacher, CFO, Therapix Biosciences, josh@therapixbio.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/therapix-biosciences-to-present-at-upcoming-scientific-and-investor-conferences-in-june-300465279.html
SOURCE Therapix Biosciences Ltd